Unbelievable Folly of Clinical Trials in Heart Failure
Author:
- 1 April 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 9 (4) , e002837
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The First-in-man Randomized Trial of a Beta3 Adrenoceptor Agonist in Chronic Heart Failure: The BEAT-HF TrialEuropean Journal of Heart Failure, 2016
- Isosorbide Mononitrate in Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2015
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection FractionJAMA, 2015
- LCZ696 (Sacubitril/Valsartan)JACC, 2015
- A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptomsHeart Failure Reviews, 2015
- Cardiovascular Drug DevelopmentJACC, 2015
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2013
- Stopping clinical trials early for benefit: impact on estimationClinical Trials, 2009
- Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trialAmerican Heart Journal, 2001
- Current perspectives on the design of phase II trials of new drugs for the treatment of heart failureAmerican Heart Journal, 2000